Logo
x

Search category

Subscribe Now

Gene Therapy

Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis

Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis

  • July 9, 2021
Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis

Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis

  • July 9, 2021
Bayer to Advance its Investigational Cell and Gene Therapy for Parkinson's Disease

Bayer to Advance its Investigational Cell and Gene Therapy for Parkinson's Disease

  • June 9, 2021
Bayer to Advance its Investigational Cell and Gene Therapy for Parkinson's Disease

Bayer to Advance its Investigational Cell and Gene Therapy for Parkinson's Disease

  • June 9, 2021
Charles River to Acquire Vigene Biosciences for $292.5M

Charles River to Acquire Vigene Biosciences for $292.5M

  • May 17, 2021
Charles River to Acquire Vigene Biosciences for $292.5M

Charles River to Acquire Vigene Biosciences for $292.5M

  • May 17, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.